Neoplasm

Oncology
8
Pipeline Programs
9
Companies
11
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
7
1
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
133%
Monoclonal Antibody
133%
ADC
133%
+ 7 programs with unclassified modality

Competitive Landscape

8 companies ranked by most advanced pipeline stage

M&
Merck & Co.RAHWAY, NJ
2 programs
1
1
MK2461Phase 1/21 trial
DalotuzumabPhase 1Monoclonal Antibody1 trial
Active Trials
NCT00694356Completed15Est. Apr 2009
NCT00496353Completed26Est. Nov 2008
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
2 programs
1
BI 891065Phase 11 trial
ARBN/A2 trials
Active Trials
NCT07472517Not Yet Recruiting670Est. Apr 2029
NCT02215733Completed1,165,781
NCT04138823Completed12Est. May 2023
Eli Lilly and Company
Eli Lilly and CompanyINDIANAPOLIS, IN
1 program
1
AbemaciclibPhase 1Small Molecule1 trial
Active Trials
NCT02117648Completed26Est. Aug 2015
GS
Gilead SciencesFOSTER CITY, CA
1 program
1
COM503Phase 11 trial
Active Trials
NCT06759649Recruiting200Est. Nov 2027
Pfizer
PfizerNEW YORK, NY
1 program
1
PF-00337210Phase 11 trial
Active Trials
NCT01105533Completed46Est. Sep 2011
Sanofi
SanofiPARIS, France
1 program
1
Tusamitamab ravtansinePhase 1ADC1 trial
Active Trials
NCT05429762Terminated56Est. Apr 2024
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
1
[14C] AZD6738Phase 11 trial
Active Trials
NCT06754761Not Yet Recruiting8Est. Aug 2025
SpringWorks Therapeutics
1 program
PF-03084014N/A1 trial
Active Trials
NCT02955446No Longer Available

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
Boehringer IngelheimARB
Merck & Co.MK2461
AstraZeneca[14C] AZD6738
Gilead SciencesCOM503
SanofiTusamitamab ravtansine
Boehringer IngelheimBI 891065
Eli Lilly and CompanyAbemaciclib
Merck & Co.Dalotuzumab
PfizerPF-00337210
Boehringer IngelheimARB

Clinical Trials (11)

Total enrollment: 1,166,840 patients across 11 trials

NCT07472517Boehringer IngelheimARB

DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemotherapy

Start: Apr 2026Est. completion: Apr 2029670 patients
Phase 3Not Yet Recruiting
NCT00496353Merck & Co.MK2461

MK2461 Phase I/II Study in Patients With Advanced Solid Tumors (MK-2461-002 AM1)(COMPLETED)

Start: Jun 2007Est. completion: Nov 200826 patients
Phase 1/2Completed
NCT06754761AstraZeneca[14C] AZD6738

Human ADME Study of [14C]-Ceralasertib (AZD6738) and Absolute Bioavailability of Ceralasertib

Start: Jan 2025Est. completion: Aug 20258 patients
Phase 1Not Yet Recruiting
NCT06759649Gilead SciencesCOM503

A Clinical Trial to Assess COM503 in Participants With Advanced Solid Malignancies

Start: Jan 2025Est. completion: Nov 2027200 patients
Phase 1Recruiting
NCT05429762SanofiTusamitamab ravtansine

Effect of Tusamitamab Ravtansine on QTc Interval in Participants With Metastatic Solid Tumors

Start: Oct 2022Est. completion: Apr 202456 patients
Phase 1Terminated
NCT04138823Boehringer IngelheimBI 891065

A Study to Test Different Doses of BI 891065 Alone and in Combination With BI 754091 in Asian Patients With Different Types of Advanced Cancer (Solid Tumours)

Start: Nov 2019Est. completion: May 202312 patients
Phase 1Completed
NCT02117648Eli Lilly and CompanyAbemaciclib

A Study of LY2835219 in Participants With Cancer

Start: Apr 2014Est. completion: Aug 201526 patients
Phase 1Completed
NCT00694356Merck & Co.Dalotuzumab

Study of Dalotuzumab (MK-0646) in Adults With Solid Tumors (MK-0646-009)

Start: Aug 2008Est. completion: Apr 200915 patients
Phase 1Completed
NCT01105533PfizerPF-00337210

A Dose Finding Study Of A New Medication, PF-00337210 That Will Possibly Decrease Blood Supply To Tumors

Start: May 2006Est. completion: Sep 201146 patients
Phase 1Completed
NCT02955446SpringWorks TherapeuticsPF-03084014

Compassionate Use Protocol for PF-03084014 in Patients With Advanced Solid Tumor Malignancies

N/ANo Longer Available
NCT02215733Boehringer IngelheimARB

The Use of Angiotensin Receptor Blockers and the Risk of Cancer

Start: Feb 20111,165,781 patients
N/ACompleted

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
4h ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
4h ago

Office Administrator

SystImmune
4h ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
4h ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
4h ago

Working Student Active Sourcing Support (m/f/d)

Mindpeak
Hamburg
4h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 1,166,840 patients
9 companies competing in this space

Related Indications

Breast Cancer(577)Prostate Cancer(385)Non-small Cell Lung Cancer(378)Multiple Myeloma(359)Cancer(249)Advanced Solid Tumors(226)Acute Myeloid Leukemia(209)Neoplasms(199)Colorectal Cancer(171)Melanoma(170)